论文部分内容阅读
采用发色底物法检测６１例视网膜静脉阻塞（ＲＶＯ）患者血浆组织纤溶酶原激活剂（ｔ－ＰＡ）及纤溶酶原激活剂抑制物（ＰＡＩ）活性。正常对照组ｔ－ｐＡ活性２．０７±０．４０ＩＵ／ｍｌ，ＰＡＩ活性７．３３±０．６７ＡＵ／ｍｌ。ＲＶＯ患者ｔ－ＰＡ活性显著降低（１．６９±０．５６ＩＵ／ｍｌ，ｐ＜０．０１），ＰＡＩ活性显著增高（８．８０±１．６０ＡＵ／ｍｌ，Ｐ＜０．０１）。其中缺血型较非缺血型ｔ－ｐＡ活性更低（分别为１．３５±０．４３ＩＵ／ｍｌ，１．９２±０．５３ＩＵ／ｍｌ，Ｐ＜０．０１），ＰＡＩ活性更高（分别为９．３５±１．３７ＩＵ／ｍｌ，８．４２±１．２９ＩＵ／ｍｌ，Ｐ＜０．０１）．并且，这些改变随病情严重程度的加重而愈显著。
The chromogenic substrate method was used to detect the plasma level of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) in 61 patients with retinal vein occlusion (RVO). The normal control group had t-pA activity of 2.07 ± 0.40IU / ml and PAI activity of 7.33 ± 0.67AU / ml. The activity of t-PA in RVO patients was significantly lower (1.69 ± 0.56 IU / ml, p <0.01), PAI activity was significantly higher (8.80 ± 1.60 AU / ml, P <0.01). The ischemic and non-ischemic t-pA activities were lower (1.35 ± 0.43 IU / ml, 1.92 ± 0.53 IU / ml, P <0.01) Respectively, 9.35 ± 1.37IU / ml, 8.42 ± 1.29IU / ml, P <0.01). And these changes are more pronounced with the severity of the illness.